Unveiling Distinct Proteomic Signatures in Complicated Crohn's Disease That Could Predict the Disease Course.
Laura A LucaciuRadu SeiceanAlina UifăleanMaria IlieșCristina-Adela IugaAndrada SeiceanPublished in: International journal of molecular sciences (2023)
Crohn's disease (CD) is characterized by a chronic, progressive inflammation of the gastrointestinal tract often leading to complications, such as strictures and fistulae. Currently, there are no validated tools anticipating short- and long-term outcomes at an early stage. This investigation aims to elucidate variations in protein abundance across distinct CD phenotypes with the objective of uncovering potential biomarkers implicated in disease advancement. Serum samples collected from 30 CD patients and 15 healthy age-matched controls (HC) were subjected to depletion of highly abundant proteins and to a label-free mass spectrometry analysis. Twenty-four proteins were shown to be significantly different when comparing CD with HC. Of these, WD repeat-containing protein 31 (WDR31), and proteins involved in the acute inflammatory response, leucine-rich alpha-2-glycoprotein (LRG1) and serum amyloid A1 (SAA1), were more abundant in the aggressive subgroup. Against standard biomarkers, a positive correlation between SAA1 and WDR31 and C-reactive protein (CRP) was found. In this study, a unique serum biomarker panel for aggressive CD was identified, which could aid in predicting the disease course.
Keyphrases
- early stage
- inflammatory response
- mass spectrometry
- randomized controlled trial
- end stage renal disease
- gene expression
- chronic kidney disease
- oxidative stress
- ejection fraction
- multiple sclerosis
- radiation therapy
- high resolution
- dna methylation
- clinical trial
- microbial community
- risk factors
- hepatitis b virus
- capillary electrophoresis
- intensive care unit
- genome wide
- drug induced
- simultaneous determination
- tandem mass spectrometry
- acute respiratory distress syndrome